Literature DB >> 365126

Imipramine and desipramine in plasma and spinal fluid: relationship to clinical response and serotonin metabolism.

G Muscettola, F K Goodwin, W Z Potter, M M Claeys, S P Markey.   

Abstract

In a double-blind study of depressed patients treated with imipramine hydrochloride, levels of imipramine and desipramine were measured in plasma and in CSF. Levels of both drugs in CSF were approximately 10% of plasma levels, but the levels in the two body fluids were highly correlated. The levels of both drugs were approximately equal in plasma, but desipramine predominated in CSF (imipramine/desipramine ratio of 0.8). The imipramine-induced alteration in CSF levels of the serotonin metabolite (5-hydroxy-indoleacetic acid [5HIAA]) correlated with imipramine levels but not with desipramine. For the group of patients showing a clear antidepressant response, the mean drug levels were nearly double those of the nonresponder group, a difference that did not quite reach statistical significance in this relatively small sample. The desipramine levels showed no responder-nonresponder difference, while the ratio of imipramine/desipramine was significantly higher among the responders. On the average this particular patient group had relatively low pretreatment levels of 5HIAA in CSF, an observation that may partially account for the relatively low overall response rate to imipramine.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 365126     DOI: 10.1001/archpsyc.1978.01770290103009

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  12 in total

1.  Fluoxetine blocks Nav1.5 channels via a mechanism similar to that of class 1 antiarrhythmics.

Authors:  Hugo Poulin; Iva Bruhova; Quadiri Timour; Olivier Theriault; Jean-Martin Beaulieu; Dominique Frassati; Mohamed Chahine
Journal:  Mol Pharmacol       Date:  2014-07-15       Impact factor: 4.436

Review 2.  Pharmacokinetic optimisation of tricyclic antidepressant therapy.

Authors:  M Furlanut; P Benetello; E Spina
Journal:  Clin Pharmacokinet       Date:  1993-04       Impact factor: 6.447

Review 3.  Clinical pharmacokinetics of cerebrospinal fluid.

Authors:  M Bonati; J Kanto; G Tognoni
Journal:  Clin Pharmacokinet       Date:  1982 Jul-Aug       Impact factor: 6.447

4.  Plasma protein binding of imipramine in patients with rheumatoid arthritis.

Authors:  C B Kristensen
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

5.  Plasma protein binding of perazine and amitriptyline in psychiatric patients.

Authors:  M Brinkschulte; H J Gaertner; H W Schied; U Breyer-Pfaff
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

6.  Norepinephrine and serotonin metabolism and clinical response to combined imipramine and amitriptyline therapy in depression.

Authors:  V Palaniappun; V Ramachandran; O Somasundaram
Journal:  Indian J Psychiatry       Date:  1991-07       Impact factor: 1.759

Review 7.  Steady-state kinetics of doxepin and imipramine in Saudi patients with interethnic comparison.

Authors:  A el-Yazigi; K Chaleby
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

8.  Prediction of steady state plasma and saliva levels of desmethylimipramine using a single dose, single time point procedure.

Authors:  T B Cooper; N Bark; G M Simpson
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

9.  The effect of clorgyline on noradrenergic function.

Authors:  R J Ross; M Scheinin; P Lesieur; M V Rudorfer; R L Hauger; L J Siever; M Linnoila; W Z Potter
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

Review 10.  Pharmacokinetic optimisation of therapy with newer antidepressants.

Authors:  P J Goodnick
Journal:  Clin Pharmacokinet       Date:  1994-10       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.